Proteon Therapeutics, Inc. (PRTO)

[Whalatane]

Jt What interests my wife and I the most is the 34% reduction in the risk of secondary Patency loss over 1 yr compared to placebo .
Thats really clinically important to her ....34% reduction in loss of Patency .

What concerns me the most tho is the P value of this data 0.048

The only difference between the first P3 and this final P3 ( besides the endpts ) is that they have recruited 600 patients instead of 300.

Is that enough to see a significant improvement in the P value ....and excuse my biostatistics ignorance but how exactly does that work ?
Thx
Kiwi